N-[5-[4,5-bis(ethenyl)-1H-imidazol-2-yl]-1H-pyrazol-3-yl]-3-chloro-4-(2-hydroxyethylamino)benzamide
C19H19ClN6O2 — CID 163228078
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[5-[4,5-bis(ethenyl)-1H-imidazol-2-yl]-1H-pyrazol-3-yl]-3-chloro-4-(2-hydroxyethylamino)benzamide
N-[5-[4,5-bis(ethenyl)-1H-imidazol-2-yl]-1H-pyrazol-3-yl]-3-chloro-4-(2-hydroxyethylamino)benzamide (PubChem CID 163228078) has the molecular formula C19H19ClN6O2 and a molecular weight of 398.85 g/mol. Its IUPAC name is N-[5-[4,5-bis(ethenyl)-1H-imidazol-2-yl]-1H-pyrazol-3-yl]-3-chloro-4-(2-hydroxyethylamino)benzamide.
Molecular Properties
| Compound Name | N-[5-[4,5-bis(ethenyl)-1H-imidazol-2-yl]-1H-pyrazol-3-yl]-3-chloro-4-(2-hydroxyethylamino)benzamide |
|---|---|
| PubChem CID | 163228078 |
| Molecular Formula | C19H19ClN6O2 |
| Molecular Weight | 398.85 g/mol |
| Exact Mass | 398.13 |
| IUPAC Name | N-[5-[4,5-bis(ethenyl)-1H-imidazol-2-yl]-1H-pyrazol-3-yl]-3-chloro-4-(2-hydroxyethylamino)benzamide |
| SMILES | C=Cc1nc(-c2cc(NC(=O)c3ccc(NCCO)c(Cl)c3)n[nH]2)[nH]c1C=C |
| InChI | InChI=1S/C19H19ClN6O2/c1-3-13-14(4-2)23-18(22-13)16-10-17(26-25-16)24-19(28)11-5-6-15(12(20)9-11)21-7-8-27/h3-6,9-10,21,27H,1-2,7-8H2,(H,22,23)(H2,24,25,26,28) |
| InChIKey | BQRCKEXROAFRHH-UHFFFAOYSA-N |
| XLogP | 3.40 |
| TPSA | 118.72 Ų |
| H-Bond Donors | 5 |
| H-Bond Acceptors | 5 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 28 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 398.85 |
| LogP ≤ 5 | 3.40 |
| H-Bond Donors ≤ 5 | 5 |
| H-Bond Acceptors ≤ 10 | 5 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 163228078 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.